Who
Mark Ragosa
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kiniksa Pharmaceuticals International.
In numbers
- Trades disclosed
- 247
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $15.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Dec 2020
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,694 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,694 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,750 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,591 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —31,150 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,069 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,591 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,694 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —3,069 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code F | $349K4,404 at $79.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —31,150 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,069 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,591 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,694 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,750 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,591 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Mark Ragosa; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.